Literature DB >> 15708451

Temporal evolution of mouse striatal gene expression following MPTP injury.

R M Miller1, L L Chen, G L Kiser, T L Giesler, T M Kaysser-Kranich, C Palaniappan, H J Federoff.   

Abstract

The gradual loss of striatal dopamine and dopaminergic neurons residing in the substantia nigra (SN) causes parkinsonism characterized by slow, halting movements, rigidity, and resting tremor when neuronal loss exceeds a threshold of approximately 80%. It is estimated that there is extensive compensation for several years prior to symptom onset, during which vulnerable neurons asynchronously die. Recent evidence would argue that much of the compensatory response of the nigrostriatal system is multimodal including both pre-synaptic and striatal mechanisms. Although parkinsonism may have multiple causes, the classic syndrome, Parkinson's disease (PD), is frequently modeled in small animals by repeated administration of the selective neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Because the MPTP model of PD recapitulates many of the known behavioral and pathological features of human PD, we asked whether the striatal cells of mice treated with MPTP in a semi-chronic paradigm enact a transcriptional program that would help elucidate the response to dopamine denervation. Our findings reveal a time-dependent dysregulation in the striatum of a set of genes whose products may impact both the viability and ability to communicate of dopamine neurons in the SN.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15708451     DOI: 10.1016/j.neurobiolaging.2004.12.002

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  6 in total

Review 1.  Microarrays in Parkinson's disease: a systematic approach.

Authors:  Renee M Miller; Howard J Federoff
Journal:  NeuroRx       Date:  2006-07

2.  Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

Authors:  R Pattarini; Y Rong; C Qu; J I Morgan
Journal:  Neuroscience       Date:  2008-07-08       Impact factor: 3.590

Review 3.  Current status and future directions of gene expression profiling in Parkinson's disease.

Authors:  James G Greene
Journal:  Neurobiol Dis       Date:  2010-11-05       Impact factor: 5.996

4.  Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease.

Authors:  Mark H Chin; Wei-Jun Qian; Haixing Wang; Vladislav A Petyuk; Joshua S Bloom; Daniel M Sforza; Goran Laćan; Dahai Liu; Arshad H Khan; Rita M Cantor; Diana J Bigelow; William P Melega; David G Camp; Richard D Smith; Desmond J Smith
Journal:  J Proteome Res       Date:  2008-02       Impact factor: 4.466

5.  Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model.

Authors:  Xin Qi; Brandon Davis; Yung-Hsiao Chiang; Emily Filichia; Austin Barnett; Nigel H Greig; Barry Hoffer; Yu Luo
Journal:  J Neurochem       Date:  2016-07-15       Impact factor: 5.372

6.  Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons.

Authors:  Yofre Cabeza-Arvelaiz; Sheila M Fleming; Franziska Richter; Eliezer Masliah; Marie-Francoise Chesselet; Robert H Schiestl
Journal:  Mol Neurodegener       Date:  2011-12-13       Impact factor: 14.195

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.